News | ECG | February 14, 2022

MediLynx Partners with NHLBI & NIH on Study of Efficacy of Mobile Cardiac Monitoring for Patients

The objective of the Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG (PACeS) Digital Health Substudy is to quantify the burden of POAF after isolated Coronary Artery Bypass Graft (CABG) surgery among enrolled patients.

MediLynx Cardiac Monitoring, LLC (dba MediLynx Arrhythmia Diagnostics), a national remote monitoring provider and technology leader in deep learning artificial intelligence, has announced a partnership with the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN) to participate in a multicenter randomized clinical trial substudy of its PocketECG technology.

PocketECG


February 14, 2022 MediLynx Cardiac Monitoring, LLC (dba MediLynx Arrhythmia Diagnostics), a national remote monitoring provider and technology leader in deep learning artificial intelligence, has announced a partnership with the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN) to participate in a multicenter randomized clinical trial substudy of its PocketECG technology.

MediLynx’s PocketECG 4 combines advances in mobile data transmission, artificial intelligence, and cloud computing, in a novel device that provides for monitoring of continuous ECG for patients. The technology allows for streaming of every heartbeat to a cloud-based platform where the continuous signal is processed in near real-time by a Convolutional Neural Network with a super-deep structure of over 100 layers. ECG streaming combined with advanced cloud computing is ideally suited to accurately measure and predict Post-Operative Atrial Fibrillation (POAF).

The objective of the Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG (PACeS) Digital Health Substudy is to quantify the burden of POAF after isolated Coronary Artery Bypass Graft (CABG) surgery among enrolled patients.

The project will involve monitoring post-CABG patients for 30 days to determine the incidence of Atrial Fibrillation (AF). This is particularly important as post surgery AF can increase patient mortality.  The study will involve the monitoring of 500 patients over a period of approximately four years.

Continuous Mobile Cardiac Telemetry (MCT) will be used to monitor patient heart rhythm for 30 days after hospital discharge. The secondary aim of this substudy will be to perform an exploratory analysis using MCT data that characterizes patterns of digital phenotyping for recurrent AF among POAF patients.  Specifically, continuous MCT data will be used to explore three aspects of digital phenotyping: (1) actigraphy, (2) heart rate variability, and (3) micro-AF and Premature Atrial Contractions (PACs).

“The key to effective care management is identifying better solutions through research,” said William Moody, Chief Operating Officer at MediLynx. “This novel technology can properly assist physicians in identifying arrhythmias in patients, and accurately help determine the burden of such occurrence.  MediLynx is honored to be selected by the NHLBI/NIH-funded CTSN to collaborate with more than 25 academic institutions on this exciting research study.  MediLynx’s PocketECG solution was selected because of our modern engineering and proven clinical efficacy in cardiac monitoring.”

About the Trial

The PACeS Digital Health Substudy is a 500 patient study of a multicenter randomized clinical trial and will be conducted in highly experienced clinical centers participating in the CTSN.  The estimated enrollment period is 48 months, and all participants will be provided with PocketECG devices for 30 days from the date of discharge. 

For more information: https://medilynx.com/

Related Wearable ECG Monitoring Content:

How Advances in Wearable Cardiac Monitors Improve the Patient and Clinician Experience

Longer Continuous Ambulatory Cardiac Monitoring Enables More Comprehensive Evaluation of Atrial Fibrillation

Cardea Solo Wearable ECG Collects High-altitude Cardiac Data on Denali Expedition

Cardiac Insight Partners With VivoSense for Cardiovascular Research

Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation

As Interpretation Criteria Evolve, False Positive Athlete ECG Screening Rates Can Decrease

Related Content

News | ECG

April 12, 2022 – Biotricity, a medical diagnostic and consumer healthcare technology company, will officially launch the ...

Home April 12, 2022
Home
News | ECG

April 4, 2022 – GE Healthcare and AliveCor have announced a partnership to deliver medical-grade six-lead ...

Home April 04, 2022
Home
News | ECG
February 11, 2022 – Philips, a global leader in health technology, announced the introduction of the industry’s first ...
Home February 11, 2022
Home
News | ECG

September 1, 2021 — University of South Australia researchers have designed a computer vision system that can ...

Home September 01, 2021
Home
News | ECG

June 18, 2021 — You might be older ― or younger ― than you think. A new study found that differences between a person's ...

Home June 18, 2021
Home
News | ECG

February 16, 2021 — QT Medical recently announced the launch of Xpress ECG service, the world’s first 12-lead ECG home ...

Home February 16, 2021
Home
News | ECG

February 2, 2021 — Cardiac Insight, Inc. a healthcare company specializing in wearable cardiac sensors and automated ...

Home February 02, 2021
Home
Feature | ECG | By Dave Fornell, Editor

Here are a few trends to watch for in electrocardiogram (ECG, or if you prefer the original German EKG) systems. The ...

Home January 20, 2021
Home
Feature | ECG

Apple created a stir when it announced in 2018 that its Apple Watch Series 4 was the first consumer health and fitness ...

Home March 11, 2020
Home
Feature | ECG

When the patients of Michael Boler, M.D. need cardiac monitoring, the Holter monitor is no longer his first choice. “The ...

Home February 19, 2020
Home
Subscribe Now